OpenAI Acquires Orchestra Bio for Rosalind Initiative

OpenAI has acquired Orchestra Bio, a startup whose software uses AI agents to help manage drug-development programs, and plans to add its team and technology to its Rosalind life-sciences initiative. The companies did not disclose the acquisition price or when Orchestra’s capabilities will be integrated. Announced October 20, the deal expands OpenAI’s work on tools for biology and drug research. Rosalind includes models and software designed to help researchers investigate scientific questions, analyze data and plan experiments. Orchestra’s platform focuses on coordinating the operational work required to advance a potential medicine. According to OpenAI, Orchestra’s agents track tasks and milestones across a drug program, identify which work could be affected by a disruption and help teams compare possible responses. In one example described by the company, a failed manufacturing batch could delay a clinical trial and require teams to reassess connected milestones. Scientists and program leaders would retain responsibility for decisions. The acquisition links tools for scientific research with software intended to help manage what follows a discovery. Drug development...